The Food and Drug Administration will prioritize regulatory guidance for artificial intelligence-enabled devices and surgical robots over the coming year. The agency intends to finalize guidance for AI-enabled devices and draft new advice on generative AI, according to a report from Healthcare Dive.
The move reflects an effort to keep pace with rapidly evolving medical technology. Surgical robots are also on the agenda, as the FDA looks to clarify expectations for these devices.
Specific timelines and details of the guidance were not disclosed, but the focus signals increasing regulatory attention to AI and robotics in healthcare.